Skip to main content
OpenTrials
Completed

NCT Number: NCT02230501

Metabolic Activation With Protein-rich Formula Diet

Formerly, the investigators demonstrated in an uncontrolled proof-of principle study (NCT 01680926) that protein-rich meal replacement (PRMR) was successful in reducing daily insulin demand, HbA1c and weight in type 2 diabetes mellitus (T2DM) patients injecting >100 IE insulin/day. The aim of the present study was to investigate in a randomized-controlled trial if PRMR is also effective in T2DM patients treated with oral antidiabetic medication or insulin.

A second part of the study is an open-label registry for persons with type 2 diabetes, who will perform the lifestyle intervention with the stringent diet regime.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

West German Centre of Diabetes and Health

Düsseldorf, 40591, Germany

About this study

Type 2 diabetes mellitus (T2DM) patients had been randomized into two groups. During the 1st week the intervention group with stringent diet regime replaced 3 main meals by 50 g PRMR (Almased-Vitalkost, Almased Wellness GmbH, Bienenbüttel, Germany) each (=1100 kcal/day). In 2nd-4th week 2 meals were replaced and a protein-rich lunch was allowed. In 5th-12th week only dinner was replaced. The control group with moderate diet regime replaced breakfast and dinner for 4 weeks and then only dinner during the next 8 weeks. Clinical parameters were determined at the study center at baseline, after 4, 8 and 12 weeks. Primary endpoint was reduction of HbA1c, secondary endpoints reduction of weight and antidiabetic medication.

In the second part of the study type 2 diabetes patients are included in an open-label reistry and perform the lifestyle intervention with the stringent diet regime.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes mellitus
  • HbA1c > 7,5%
  • Body Mass Index (BMI) ≥ 27,5 kg/m2

Exclusion criteria

  • acute infections
  • severe diseased with hospital stay during the last 3 months
  • chronic diseases
  • chemotherapy or cortisone treatment
  • weight loss of more than 2 kg per week during the last month
  • smoking cessation during the last 3 months or planned
  • weight-influencing medication
  • pregnancy, breast-feeding or lack of contraception
  • high-level physical activity of more than 1h per day
  • incompatibility with components of the PRMR
  • participation in an other study during the last 6 months

For the open-label registry, the only inclusion criterium is type 2 diabetes.

Treatment and study plan

stringent diet regimen

Dietary Supplement

Other names: protein-rich meal replacement (PRMR), i.e Almased-Vitalkost (Almased Wellness GmbH, Bienenbüttel, Germany)

moderate diet regimen

Dietary Supplement

Other names: protein-rich meal replacement (PRMR), i.e Almased-Vitalkost (Almased Wellness GmbH, Bienenbüttel, Germany)

Primary outcomes

  1. HbA1c

    Time frame: 12 weeks

    change in hemoglobin A1c

Secondary outcomes

  1. HbA1c

    Time frame: 1 year

    change in hemoglobin A1c

  2. body weight

    Time frame: 12 weeks and 1 year

    change in body weight

  3. blood pressure

    Time frame: 12 weeks and 1 year

    change in systolic and diastolic blood pressure

  4. cholesterol

    Time frame: 12 weeks and 1 year

    change in total cholesterol change in HDL cholesterol change in LDL cholesterol

  5. fasting blood glucose

    Time frame: 12 weeks and 1 year

    change in fastin g blood glucose

  6. quality of life

    Time frame: 12 weeks and 1 year

    change in SF-36 quality of life questionnaire change in ADS-L (German version of the general depression scale)

  7. nutrition

    Time frame: 12 weeks and 1 year

    change in FEV (questionnaire for eating manners)

  8. physical activity

    Time frame: 12 weeks and 1 year

    change in physical activity questionnaire

  9. antidiabetic medication

    Time frame: 12 weeks and 1 year

    • absolute amount of antidiabetic medication
    • increase or reduction

Sponsors and collaborators

Lead sponsor

West German Center of Diabetes and Health

Other

Collaborators

  • Almased Wellness GmbH

Registry information

Official study title

Metabolic Activation With Protein-rich Formula Diet - a Randomized-controlled Trial

Acronym: AVS

Important dates

Study start
2011
Primary completion
2023
Study completion
2023
First posted
Sep 3, 2014
Registry last updated
Jan 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.